Just days after pharmaceutical conglomerate AbbVie said it was reconsidering its plans to acquire Shire due to recent crackdowns on inversion mergers, reports say the merger is officially cancelled, and that AbbVie will pay a breakup fee to Shire.
AbbVie had planned to acquire Shire for $55 billion in a takeover that would also relocate AbbVie’s tax bracket overseas to the UK. The merger would result in lower taxes for AbbVie.
But authorities in both the US and EU have recently upped criticism over such mergers; the European Commission is currently investigating whether they constitute illegal state aid, and the US introduced new limitations on the tax benefits corporations can enjoy through such mergers.
AbbVie confirmed that it has cancelled plans to acquire Shire and said it will pay the $1.64 billion breakup fee previously agreed upon.
Full content: CNBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Justice Department Moves to End NCAA Transfer Rule
May 30, 2024 by
CPI
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 31, 2024 by
CPI
AI and Antitrust Considerations in U.S. Health Care
May 31, 2024 by
CPI
Uncertainty in the Bottom Line: New Antitrust Scrutiny and Enforcement in Private Equity Transactions
May 31, 2024 by
CPI
Effecting M&A Diligence When Competitors Are Involved
May 31, 2024 by
CPI
AI, Pharmaceutical Sector, and EU Competition Law and Policy: What Does the Future Look Like?
May 31, 2024 by
CPI